Indapamide

Indapamide

Clinical data
Routes of administration	Oral
ATC code	C03BA11 (WHO)
Pharmacokinetic data
Protein binding	71-79%
Metabolism	Hepatic
Elimination half-life	14-18 hours
Identifiers
IUPAC name 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)- 3-sulfamoyl-benzamide
CAS Number	26807-65-8
PubChem CID	3702
DrugBank	APRD01031
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H16ClN3O3S
Molar mass	365.835 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Indapamide is a non-thiazide sulphonamide diuretic drug marketed by Servier, generally used in the treatment of hypertension and edema caused by congestive heart failure. Indapamide is marketed as Natrilix SR (sustained release). Combination preparations with perindopril (an ACE inhibitor antihypertensive) are also available.

Form and composition

Each sustained-release coated tablet contains 1.5 mg of 1-(4-chloro-3-sulfamyl-benzamido)-2-methylindoline (or indapamide hemihydrate).

Indications

Essential hypertension.

Dosage and administration

One tablet daily.

Contraindications

Indapamide is contraindicated in known hypersensitivity to sulfonamides, severe renal failure, hepatic encephalopathy or severe hepatic failure and hypokalemia (low blood potassium levels).

There is insufficient safety data to recommend indapamide use in pregnancy or breastfeeding.

Interactions

Caution is advised in the combination of indapamide with lithium and nonantiarrhythmic drugs causing wave burst arrhythmia (astemizole, bepridil, IV erythromycin, halofantrine, pentamidine, sultopride, terfenadine, vincamine).

Precautions

Monitoring of potassium and uric acid serum levels is recommended, especially in subjects with a predisposition or a sensitivity to hypokalemia and in patients with gout.

Adverse effects

Commonly reported adverse events are hypokalemia (low potassium levels), fatigue, orthostatic hypotension (blood pressure decrease on standing up) and allergic manifestations.

Overdosage

Symptoms of overdosage would be those associated with a diuretic effect: electrolyte disturbances, hypotension, and muscular weakness. Treatment should be symptomatic, directed at correcting the electrolyte abnormalities.

hr:Indapamid hu:Indapamid